{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,3,13]],"date-time":"2026-03-13T13:44:15Z","timestamp":1773409455621,"version":"3.50.1"},"reference-count":84,"publisher":"Elsevier BV","issue":"3","license":[{"start":{"date-parts":[[2009,9,1]],"date-time":"2009-09-01T00:00:00Z","timestamp":1251763200000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/tdm\/userlicense\/1.0\/"}],"content-domain":{"domain":[],"crossmark-restriction":false},"short-container-title":["Best Practice & Research Clinical Haematology"],"published-print":{"date-parts":[[2009,9]]},"DOI":"10.1016\/j.beha.2009.04.005","type":"journal-article","created":{"date-parts":[[2009,12,2]],"date-time":"2009-12-02T10:19:00Z","timestamp":1259749140000},"page":"343-353","source":"Crossref","is-referenced-by-count":13,"title":["Prognostic factors in chronic myeloid leukaemia"],"prefix":"10.1016","volume":"22","author":[{"given":"Juan Carlos","family":"Hern\u00e1ndez-Boluda","sequence":"first","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Francisco","family":"Cervantes","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]}],"member":"78","reference":[{"key":"10.1016\/j.beha.2009.04.005_bib1","doi-asserted-by":"crossref","first-page":"1489","DOI":"10.1001\/jama.1924.02650450001001","article-title":"Chronic myelogenous leukemia","volume":"82","author":"Minot","year":"1924","journal-title":"JAMA"},{"key":"10.1016\/j.beha.2009.04.005_bib2","doi-asserted-by":"crossref","first-page":"398","DOI":"10.1182\/blood.V82.2.398.398","article-title":"Randomized comparison of busulfan and hydroxyurea in chronic myelogenous leukemia: prolongation of survival by hydroxyurea. The German CML Study Group","volume":"82","author":"Hehlmann","year":"1993","journal-title":"Blood"},{"key":"10.1016\/j.beha.2009.04.005_bib3","doi-asserted-by":"crossref","first-page":"4064","DOI":"10.1182\/blood.V84.12.4064.bloodjournal84124064","article-title":"Randomized comparison of interferon-alpha with busulfan and hydroxyurea in chronic myelogenous leukemia. The German CML Study Group","volume":"84","author":"Hehlmann","year":"1994","journal-title":"Blood"},{"key":"10.1016\/j.beha.2009.04.005_bib4","doi-asserted-by":"crossref","first-page":"820","DOI":"10.1056\/NEJM199403243301204","article-title":"The Italian cooperative study group on chronic myeloid leukemia. Interferon alfa-2a as compared with conventional chemotherapy for the treatment of chronic myeloid leukemia","volume":"330","year":"1994","journal-title":"N Engl J Med"},{"key":"10.1016\/j.beha.2009.04.005_bib5","doi-asserted-by":"crossref","first-page":"1392","DOI":"10.1016\/S0140-6736(95)92596-1","article-title":"The UK medical research council's working parties for therapeutic trials in adult leukaemia","volume":"345","author":"Allan","year":"1995","journal-title":"Lancet"},{"key":"10.1016\/j.beha.2009.04.005_bib6","doi-asserted-by":"crossref","first-page":"1616","DOI":"10.1093\/jnci\/89.21.1616","article-title":"Chronic myeloid leukemia trialist' collaborative group. Interferon alfa versus chemotherapy for chronic myeloid leukemia: a meta-analysis of seven randomized trials","volume":"89","year":"1997","journal-title":"J Natl Cancer Inst"},{"key":"10.1016\/j.beha.2009.04.005_bib7","doi-asserted-by":"crossref","first-page":"3074","DOI":"10.1182\/blood.V98.10.3074","article-title":"Chronic myeloid leukemia and interferon-alpha: a study of complete cytogenetic responders","volume":"98","author":"Bonifazi","year":"2001","journal-title":"Blood"},{"key":"10.1016\/j.beha.2009.04.005_bib8","doi-asserted-by":"crossref","first-page":"223","DOI":"10.1056\/NEJM199707243370402","article-title":"Interferon alfa-2b combined with cytarabine versus interferon alone in chronic myelogenous leukemia. French chronic myeloid leukemia study group","volume":"337","author":"Guilhot","year":"1997","journal-title":"N Engl J Med"},{"key":"10.1016\/j.beha.2009.04.005_bib9","doi-asserted-by":"crossref","first-page":"1527","DOI":"10.1182\/blood.V99.5.1527","article-title":"A randomized study of interferon-alpha versus interferon-alpha and low-dose arabinosyl cytosine in chronic myeloid leukemia","volume":"99","author":"Baccarani","year":"2002","journal-title":"Blood"},{"key":"10.1016\/j.beha.2009.04.005_bib10","doi-asserted-by":"crossref","first-page":"993","DOI":"10.1046\/j.1365-2141.2000.02216.x","article-title":"Chronic myelogenous leukaemia","volume":"111","author":"Lee","year":"2000","journal-title":"Br J Haematol"},{"key":"10.1016\/j.beha.2009.04.005_bib11","doi-asserted-by":"crossref","first-page":"1087","DOI":"10.1016\/S0140-6736(98)03030-X","article-title":"Risk assessment for patients with chronic myeloid leukaemia before allogeneic bone marrow transplantation","volume":"352","author":"Gratwohl","year":"1998","journal-title":"Lancet"},{"key":"10.1016\/j.beha.2009.04.005_bib12","doi-asserted-by":"crossref","first-page":"1613","DOI":"10.1038\/sj.leu.2403821","article-title":"A 10-year median follow-up study after allogeneic stem cell transplantation for chronic myeloid leukemia in chronic phase from HLA-identical sibling donors","volume":"19","author":"Robin","year":"2005","journal-title":"Leukemia"},{"key":"10.1016\/j.beha.2009.04.005_bib13","first-page":"513","volume":"91","author":"Grahtwohl","year":"2006","journal-title":"Haematologica"},{"key":"10.1016\/j.beha.2009.04.005_bib14","doi-asserted-by":"crossref","first-page":"2969","DOI":"10.1182\/blood-2004-09-3544","article-title":"Outcomes of reduced-intensity transplantation for chronic myeloid leukemia: an analysis of prognostic factors from the chronic leukemia working party of the EBMT","volume":"106","author":"Crawley","year":"2005","journal-title":"Blood"},{"key":"10.1016\/j.beha.2009.04.005_bib15","doi-asserted-by":"crossref","first-page":"1039","DOI":"10.1182\/blood-2007-07-103523","article-title":"Favorable long-term follow-up results over 6 years for response, survival, and safety with imatinib mesylate therapy in chronic-phase chronic myeloid leukemia after failure of interferon-\u03b1 treatment","volume":"111","author":"Hochhaus","year":"2008","journal-title":"Blood"},{"key":"10.1016\/j.beha.2009.04.005_bib16","doi-asserted-by":"crossref","first-page":"106","DOI":"10.1200\/JCO.2007.13.2373","article-title":"Long-term outcome of complete cytogenetic responders after imatinib 400mg in late chronic phase, Philadelphia-positive chronic myeloid leukemia: the GIMEMA Working Party on CML","volume":"26","author":"Palandri","year":"2008","journal-title":"J Clin Oncol"},{"key":"10.1016\/j.beha.2009.04.005_bib17","doi-asserted-by":"crossref","first-page":"994","DOI":"10.1056\/NEJMoa022457","article-title":"Imatinib compared with interferon and low-dose cytarabine for newly diagnosed chronic-phase chronic myeloid leukemia","volume":"348","author":"O'Brien","year":"2003","journal-title":"N Engl J Med"},{"key":"10.1016\/j.beha.2009.04.005_bib18","doi-asserted-by":"crossref","DOI":"10.1182\/blood-2008-05-158535","volume":"112","author":"O'Brien","year":"2008","journal-title":"Blood"},{"key":"10.1016\/j.beha.2009.04.005_bib19","doi-asserted-by":"crossref","first-page":"105","DOI":"10.1111\/j.1365-2141.1981.tb02765.x","article-title":"Staging of chronic myeloid leukemia","volume":"47","author":"Tura","year":"1981","journal-title":"Br J Haematol"},{"key":"10.1016\/j.beha.2009.04.005_bib20","doi-asserted-by":"crossref","first-page":"1298","DOI":"10.1182\/blood.V60.6.1298.1298","article-title":"A multivariate analysis of prognostic factors in chronic myeloid leukemia","volume":"60","author":"Cervantes","year":"1982","journal-title":"Blood"},{"key":"10.1016\/j.beha.2009.04.005_bib21","doi-asserted-by":"crossref","first-page":"789","DOI":"10.1182\/blood.V63.4.789.789","article-title":"Prognostic discrimination in \u2018good risk\u2019 chronic granulocytic leukemia","volume":"63","author":"Sokal","year":"1984","journal-title":"Blood"},{"key":"10.1016\/j.beha.2009.04.005_bib22","doi-asserted-by":"crossref","first-page":"1352","DOI":"10.1182\/blood.V66.6.1352.1352","article-title":"Prognostic discrimination among younger patients with chronic granulocytic leukemia: relevance to bone marrow transplantation","volume":"66","author":"Sokal","year":"1985","journal-title":"Blood"},{"key":"10.1016\/j.beha.2009.04.005_bib23","doi-asserted-by":"crossref","first-page":"294","DOI":"10.1182\/blood.V72.1.294.294","article-title":"Prognostic significance of additional cytogenetic abnormalities at diagnosis of Philadelphia chromosome-positive chronic granulocytic leukemia","volume":"72","author":"Sokal","year":"1988","journal-title":"Blood"},{"key":"10.1016\/j.beha.2009.04.005_bib24","doi-asserted-by":"crossref","first-page":"850","DOI":"10.1093\/jnci\/90.11.850","article-title":"A new prognostic score for survival of patients with chronic myeloid leukemia treated with interferon alfa. Writing Committee for the Collaborative CML Prognostic Factors Project Group","volume":"90","author":"Hasford","year":"1998","journal-title":"J Natl Cancer Inst"},{"key":"10.1016\/j.beha.2009.04.005_bib25","doi-asserted-by":"crossref","first-page":"738","DOI":"10.1182\/blood.V95.3.738.003k21_738_743","article-title":"Large deletions at the t(9;22) breakpoint are common and may identify a poor-prognosis subgroup of patients with chronic myeloid leukemia","volume":"95","author":"Sinclair","year":"2000","journal-title":"Blood"},{"key":"10.1016\/j.beha.2009.04.005_bib26","doi-asserted-by":"crossref","first-page":"1732","DOI":"10.1182\/blood.V98.6.1732","article-title":"Deletions of the derivative chromosome 9 occur at the time of the Philadelphia translocation and provide a powerful and independent prognostic indicator in chronic myeloid leukemia","volume":"98","author":"Huntly","year":"2001","journal-title":"Blood"},{"key":"10.1016\/j.beha.2009.04.005_bib27","doi-asserted-by":"crossref","first-page":"3581","DOI":"10.1182\/blood.V97.11.3581","article-title":"Primary chromosomal rearrangements of leukemia are frequently accompanied by extensive submicroscopic deletions and may lead to altered prognosis","volume":"97","author":"Kolomietz","year":"2001","journal-title":"Blood"},{"key":"10.1016\/j.beha.2009.04.005_bib28","doi-asserted-by":"crossref","first-page":"1283","DOI":"10.1182\/blood-2007-02-074252","article-title":"Heterogeneous prognostic impact of derivative chromosome 9 deletions in chronic myelogenous leukemia","volume":"110","author":"Kreil","year":"2007","journal-title":"Blood"},{"key":"10.1016\/j.beha.2009.04.005_bib29","first-page":"335","article-title":"The impact of the combination of baseline risk group and cytogenetic response on the survival of patients with chronic myeloid leukemia treated with interferon-\u03b1","volume":"90","author":"Hasford","year":"2005","journal-title":"Haematologica"},{"key":"10.1016\/j.beha.2009.04.005_bib30","doi-asserted-by":"crossref","first-page":"62","DOI":"10.1182\/blood.V95.1.62","volume":"95","author":"Hochhaus","year":"2000","journal-title":"Blood"},{"key":"10.1016\/j.beha.2009.04.005_bib31","doi-asserted-by":"crossref","first-page":"4408","DOI":"10.1182\/blood-2003-10-3605","article-title":"Randomized comparison of low-dose versus high-dose interferon-alfa in chronic myeloid leukemia: prospective collaboration of 3 joint trials by the MRC and HOVON groups","volume":"103","author":"Kluin-Nelemans","year":"2004","journal-title":"Blood"},{"key":"10.1016\/j.beha.2009.04.005_bib32","doi-asserted-by":"crossref","first-page":"454","DOI":"10.1200\/JCO.2005.03.2011","article-title":"Comparison between patients with Philadelphia-positive chronic phase chronic myeloid leukemia who obtained a complete cytogenetic response within 1 year of imatinib therapy and those who achieved such a response after 12 months of treatment","volume":"24","author":"Iacobucci","year":"2006","journal-title":"J Clin Oncol"},{"key":"10.1016\/j.beha.2009.04.005_bib33","doi-asserted-by":"crossref","first-page":"1448","DOI":"10.1038\/sj.leu.2402996","article-title":"Prognostic factors for patients with chronic myeloid leukaemia in chronic phase treated with imatinib mesylate after failure of interferon alfa","volume":"17","author":"Marin","year":"2003","journal-title":"Leukemia"},{"key":"10.1016\/j.beha.2009.04.005_bib34","first-page":"1117","article-title":"Imatinib mesylate therapy of chronic phase chronic myeloid leukemia resistant or intolerant to interferon: results and prognostic factors for response and progression-free survival in 150 patients","volume":"88","author":"Cervantes","year":"2003","journal-title":"Haematologica"},{"key":"10.1016\/j.beha.2009.04.005_bib35","doi-asserted-by":"crossref","first-page":"116","DOI":"10.1002\/cncr.11863","article-title":"The significance of myelosuppression during therapy with imatinib mesylate in patients with chronic myelogenous leukemia in chronic phase","volume":"100","author":"Sneed","year":"2004","journal-title":"Cancer"},{"key":"10.1016\/j.beha.2009.04.005_bib36","doi-asserted-by":"crossref","first-page":"1979","DOI":"10.1182\/blood-2004-02-0711","article-title":"Long-term survival benefit and improved complete cytogenetic and molecular response rates with imatinib mesylate in Philadelphia chromosome-positive chronic-phase chronic myeloid leukemia after failure of interferon-alpha","volume":"104","author":"Kantarjian","year":"2004","journal-title":"Blood"},{"key":"10.1016\/j.beha.2009.04.005_bib37","doi-asserted-by":"crossref","first-page":"3794","DOI":"10.1182\/blood-2002-09-2790","article-title":"Prognostic significance of cytogenetic clonal evolution in patients with chronic myelogenous leukemia on imatinib mesylate therapy","volume":"101","author":"Cortes","year":"2003","journal-title":"Blood"},{"key":"10.1016\/j.beha.2009.04.005_bib38","doi-asserted-by":"crossref","first-page":"451","DOI":"10.1182\/blood-2003-02-0371","article-title":"Clonal evolution and lack of cytogenetic response are adverse prognostic factors for hematologic relapse of chronic phase CML patients treated with imatinib mesylate","volume":"103","author":"O'Dwyer","year":"2004","journal-title":"Blood"},{"key":"10.1016\/j.beha.2009.04.005_bib39","doi-asserted-by":"crossref","first-page":"1105","DOI":"10.1002\/cncr.11629","article-title":"Effects of age on prognosis with imatinib mesylate therapy for patients with Philadelphia chromosome-positive chronic myelogenous leukemia","volume":"98","author":"Cortes","year":"2003","journal-title":"Cancer"},{"key":"10.1016\/j.beha.2009.04.005_bib40","doi-asserted-by":"crossref","first-page":"101","DOI":"10.3324\/haematol.10239","article-title":"Impact of age on the outcome of patients with chronic myeloid leukemia in late chronic phase: results of a phase II study of the GIMEMA CML working party","volume":"92","author":"Rosti","year":"2007","journal-title":"Haematologica"},{"key":"10.1016\/j.beha.2009.04.005_bib41","doi-asserted-by":"crossref","first-page":"2281","DOI":"10.1182\/blood-2004-06-2208","article-title":"Imatinib mesylate therapy may overcome the poor prognostic significance of deletions of derivative chromosome 9 in patients with chronic myelogenous leukemia","volume":"105","author":"Quintas-Cardama","year":"2005","journal-title":"Blood"},{"key":"10.1016\/j.beha.2009.04.005_bib42","doi-asserted-by":"crossref","first-page":"1579","DOI":"10.1038\/sj.leu.2402680","article-title":"Early reduction of BCR-ABL mRNA transcript levels predicts cytogenetic response in chronic phase CML patients treated with imatinib after failure of interferon \u03b1","volume":"16","author":"Merx","year":"2002","journal-title":"Leukemia"},{"key":"10.1016\/j.beha.2009.04.005_bib43","doi-asserted-by":"crossref","first-page":"990","DOI":"10.1046\/j.1365-2141.2003.04200.x","article-title":"The early molecular response to imatinib predicts cytogenetic and clinical outcome in chronic myeloid leukaemia","volume":"120","author":"Wang","year":"2003","journal-title":"Br J Haematol"},{"key":"10.1016\/j.beha.2009.04.005_bib44","doi-asserted-by":"crossref","first-page":"1928","DOI":"10.1182\/blood.V99.6.1928","article-title":"Imatinib induces durable hematologic and cytogenetic responses in patients with accelerated phase chronic myeloid leukemia: results of a phase 2 study","volume":"99","author":"Talpaz","year":"2002","journal-title":"Blood"},{"key":"10.1016\/j.beha.2009.04.005_bib45","doi-asserted-by":"crossref","first-page":"3530","DOI":"10.1182\/blood.V99.10.3530","article-title":"Imatinib induces hematologic and cytogenetic responses in patients with chronic myelogenous leukemia in myeloid blast crisis: results of a phase II study","volume":"99","author":"Sawyers","year":"2002","journal-title":"Blood"},{"key":"10.1016\/j.beha.2009.04.005_bib46","doi-asserted-by":"crossref","first-page":"2408","DOI":"10.1056\/NEJMoa062867","article-title":"Five-year follow-up of patients receiving imatinib for chronic myeloid leukemia","volume":"355","author":"Druker","year":"2006","journal-title":"N\u00a0Engl J Med"},{"key":"10.1016\/j.beha.2009.04.005_bib47","doi-asserted-by":"crossref","first-page":"2205","DOI":"10.1182\/blood-2002-09-2763","article-title":"Imatinib improves but may not fully reverse the poor prognosis of patients with CML with derivative chromosome 9 deletions","volume":"102","author":"Huntly","year":"2003","journal-title":"Blood"},{"key":"10.1016\/j.beha.2009.04.005_bib48","doi-asserted-by":"crossref","first-page":"772","DOI":"10.1002\/cncr.23607","article-title":"No significance of chromosome 9 deletion on the clearance kinetics of BCR\/ABL fusion transcripts, cytogenetic or molecular response, loss of response, or treatment failure to imatinib mesylate therapy for chronic myeloid leukemia","volume":"113","author":"Kim","year":"2008","journal-title":"Cancer"},{"key":"10.1016\/j.beha.2009.04.005_bib49","doi-asserted-by":"crossref","DOI":"10.1182\/blood.V108.11.2112.2112","article-title":"Deletions of the derivative chromosome 9 do not influence response to imatinib of early chronic phase chronic myeloid leukemia patients. A GIMEMA working party analysis","volume":"108","author":"Castagnetti","year":"2006","journal-title":"Blood"},{"key":"10.1016\/j.beha.2009.04.005_bib50","doi-asserted-by":"crossref","first-page":"2392","DOI":"10.1038\/sj.leu.2403157","article-title":"Dynamics of BCR-ABL mRNA expression in first-line therapy of chronic myelogenous leukemia patients with imatinib or interferon \u03b1\/araC","volume":"17","author":"M\u00fcller","year":"2003","journal-title":"Leukemia"},{"key":"10.1016\/j.beha.2009.04.005_bib51","doi-asserted-by":"crossref","first-page":"1028","DOI":"10.1038\/sj.leu.2404227","article-title":"Gene expression profiling of CD34+ cells identifies a molecular signature of chronic myeloid leukemia blast crisis","volume":"20","author":"Zheng","year":"2006","journal-title":"Leukemia"},{"key":"10.1016\/j.beha.2009.04.005_bib52","doi-asserted-by":"crossref","first-page":"2794","DOI":"10.1073\/pnas.0510423103","article-title":"Gene expression changes associated with progression and response in chronic myeloid leukemia","volume":"103","author":"Radich","year":"2006","journal-title":"Proc Natl Acad Sci USA"},{"key":"10.1016\/j.beha.2009.04.005_bib53","doi-asserted-by":"crossref","first-page":"1400","DOI":"10.1038\/sj.leu.2404270","article-title":"Gene expression signature of primary imatinib-resistant chronic myeloid leukemia patients","volume":"20","author":"Frank","year":"2006","journal-title":"Leukemia"},{"key":"10.1016\/j.beha.2009.04.005_bib54","doi-asserted-by":"crossref","first-page":"205","DOI":"10.1182\/blood-2005-05-2155","article-title":"Molecular profiling of CD34+ cells identifies low expression of CD7, along with high expression of proteinase 3 or elastase, as predictors of longer survival in patients with CML","volume":"107","author":"Yong","year":"2006","journal-title":"Blood"},{"key":"10.1016\/j.beha.2009.04.005_bib55","doi-asserted-by":"crossref","first-page":"380","DOI":"10.1182\/blood-2006-12-065599","article-title":"The polycomb group BMI1 gene is a molecular marker for predicting prognosis of chronic myeloid leukemia","volume":"110","author":"Mohty","year":"2007","journal-title":"Blood"},{"key":"10.1016\/j.beha.2009.04.005_bib56","doi-asserted-by":"crossref","first-page":"155","DOI":"10.1158\/1078-0432.CCR-0784-3","article-title":"Pharmacogenomic analysis of cytogenetic response in chronic myeloid leukemia patients treated with imatinib","volume":"10","author":"Mc Lean","year":"2004","journal-title":"Clin Cancer Res"},{"key":"10.1016\/j.beha.2009.04.005_bib57","doi-asserted-by":"crossref","first-page":"1047","DOI":"10.1038\/sj.leu.2404197","article-title":"Identification of genes involved in imatinib resistance in CML: a gene-expression profiling approach","volume":"20","author":"Villuendas","year":"2006","journal-title":"Leukemia"},{"key":"10.1016\/j.beha.2009.04.005_bib58","first-page":"459","article-title":"In chronic myeloid leukemia white cells from cytogenetic responders and non-responders to imatinib have very similar gene expression signatures","volume":"90","author":"Crossman","year":"2005","journal-title":"Haematologica"},{"key":"10.1016\/j.beha.2009.04.005_bib59","doi-asserted-by":"crossref","first-page":"2520","DOI":"10.1182\/blood-2005-03-1103","article-title":"In vitro sensitivity to imatinib-induced inhibition of ABL kinase activity is predictive of molecular response in patients with de novo CML","volume":"106","author":"White","year":"2005","journal-title":"Blood"},{"key":"10.1016\/j.beha.2009.04.005_bib60","doi-asserted-by":"crossref","first-page":"697","DOI":"10.1182\/blood-2005-11-4687","article-title":"OCT-1-mediated influx is a key determinant of the intracellular uptake of imatinib but not nilotinib (AMN107): reduced OCT-1 activity is the cause of low in vitro sensitivity to imatinib","volume":"108","author":"White","year":"2006","journal-title":"Blood"},{"key":"10.1016\/j.beha.2009.04.005_bib61","doi-asserted-by":"crossref","first-page":"4064","DOI":"10.1182\/blood-2007-06-093617","article-title":"Most CML patients who have a suboptimal response to imatinib have low OCT-1 activity: higher doses of imatinib may overcome the negative impact of low OCT-1 activity","volume":"110","author":"White","year":"2007","journal-title":"Blood"},{"key":"10.1016\/j.beha.2009.04.005_bib62","doi-asserted-by":"crossref","first-page":"2368","DOI":"10.1182\/blood.V101.6.2368","article-title":"MDR1 gene overexpression confers resistance to imatinib mesylate in leukemia cell line models","volume":"101","author":"Mahon","year":"2003","journal-title":"Blood"},{"key":"10.1016\/j.beha.2009.04.005_bib63","doi-asserted-by":"crossref","first-page":"2024","DOI":"10.1182\/blood-2008-03-147744","article-title":"Multidrug resistance gene (MDR1) polymorphisms are associated with major molecular responses to standard-dose imatinib in chronic myeloid leukemia","volume":"112","author":"Dulucq","year":"2008","journal-title":"Blood"},{"key":"10.1016\/j.beha.2009.04.005_bib64","doi-asserted-by":"crossref","first-page":"2873","DOI":"10.1182\/blood-2003-11-3800","article-title":"High-dose imatinib mesylate therapy in newly diagnosed Philadelphia chromosome-positive chronic phase chronic myeloid leukemia","volume":"103","author":"Kantarjian","year":"2004","journal-title":"Blood"},{"key":"10.1016\/j.beha.2009.04.005_bib65","doi-asserted-by":"crossref","first-page":"3965","DOI":"10.1182\/blood-2008-06-161737","article-title":"Impact of early dose intensity on cytogenetic and molecular responses in chronic-phase CML patients receiving 600mg\/day of imatinib as initial therapy","volume":"112","author":"Hughes","year":"2008","journal-title":"Blood"},{"key":"10.1016\/j.beha.2009.04.005_bib66","volume":"112","author":"Cortes","year":"2008","journal-title":"Blood"},{"key":"10.1016\/j.beha.2009.04.005_bib67","doi-asserted-by":"crossref","first-page":"3358","DOI":"10.1200\/JCO.2007.15.8154","article-title":"Imatinib for newly diagnosed patients with chronic myeloid leukemia: incidence of sustained responses in an intention-to-treat analysis","volume":"26","author":"de Lavallade","year":"2008","journal-title":"J Clin Oncol"},{"key":"10.1016\/j.beha.2009.04.005_bib68","doi-asserted-by":"crossref","first-page":"1423","DOI":"10.1056\/NEJMoa030513","article-title":"Frequency of major molecular responses to imatinib or interferon alfa plus cytarabine in newly diagnosed chronic myeloid leukemia","volume":"349","author":"Hughes","year":"2003","journal-title":"N Engl J Med"},{"key":"10.1016\/j.beha.2009.04.005_bib69","doi-asserted-by":"crossref","first-page":"1809","DOI":"10.1182\/blood-2006-02-005686","article-title":"Evolving concepts in the management of chronic myeloid leukemia: recommendations from an expert panel on behalf of the European LeukemiaNet","volume":"108","author":"Baccarani","year":"2006","journal-title":"Blood"},{"key":"10.1016\/j.beha.2009.04.005_bib70","doi-asserted-by":"crossref","first-page":"4437","DOI":"10.1182\/blood-2008-06-162388","article-title":"European LeukemiaNet criteria for failure or suboptimal response reliably identify patients with CML in early chronic phase treated with imatinib whose eventual outcome is poor","volume":"112","author":"Marin","year":"2008","journal-title":"Blood"},{"key":"10.1016\/j.beha.2009.04.005_bib71","doi-asserted-by":"crossref","DOI":"10.1182\/blood-2008-06-161737","volume":"112","author":"Hughes","year":"2008","journal-title":"Blood"},{"key":"10.1016\/j.beha.2009.04.005_bib72","doi-asserted-by":"crossref","DOI":"10.1182\/blood.V112.11.2113.2113","article-title":"Long term follow up of patients with CML in chronic phase treated with first-line imatinib suggests that earlier achievement of a major molecular response leads to greater stability of response","volume":"112","author":"Branford","year":"2008","journal-title":"Blood"},{"key":"10.1016\/j.beha.2009.04.005_bib73","doi-asserted-by":"crossref","first-page":"2401","DOI":"10.1038\/sj.leu.2403158","article-title":"Imatinib produces significantly superior molecular responses compared to interferon alfa plus cytarabine in patients with newly-diagnosed chronic myeloid leukemia in chronic phase","volume":"17","author":"Branford","year":"2003","journal-title":"Leukemia"},{"key":"10.1016\/j.beha.2009.04.005_bib74","doi-asserted-by":"crossref","first-page":"29","DOI":"10.1016\/j.blre.2005.01.008","article-title":"Molecular monitoring of BCR-ABL as a guide to clinical management in chronic myeloid leukaemia","volume":"20","author":"Hughes","year":"2006","journal-title":"Blood Rev"},{"key":"10.1016\/j.beha.2009.04.005_bib75","doi-asserted-by":"crossref","first-page":"4250","DOI":"10.1182\/blood-2005-11-4406","article-title":"BCR-ABL mRNA levels at and after the time of a complete cytogenetic response (CCR) predict the duration of CCR in imatinib mesylate-treated patients","volume":"107","author":"Press","year":"2006","journal-title":"Blood"},{"key":"10.1016\/j.beha.2009.04.005_bib76","doi-asserted-by":"crossref","first-page":"3425","DOI":"10.1158\/1078-0432.CCR-04-2139","article-title":"Molecular response in patients with chronic myelogenous leukemia in chronic phase treated with imatinib mesylate","volume":"11","author":"Cortes","year":"2005","journal-title":"Clin Cancer Res"},{"key":"10.1016\/j.beha.2009.04.005_bib77","doi-asserted-by":"crossref","first-page":"4022","DOI":"10.1182\/blood-2007-10-116475","article-title":"Imatinib pharmacokinetics and its correlation with response and safety in chronic-phase chronic myeloid leukemia: a subanalysis of the IRIS study","volume":"111","author":"Larson","year":"2008","journal-title":"Blood"},{"key":"10.1016\/j.beha.2009.04.005_bib78","doi-asserted-by":"crossref","first-page":"3496","DOI":"10.1182\/blood-2006-07-036012","article-title":"Trough imatinib plasma levels are associated with both cytogenetic and molecular responses to standard-dose imatinib in chronic myeloid leukemia","volume":"109","author":"Picard","year":"2007","journal-title":"Blood"},{"key":"10.1016\/j.beha.2009.04.005_bib79","doi-asserted-by":"crossref","DOI":"10.1182\/blood.V112.11.447.447","article-title":"Imatinib pharmacokinetic exposure and its correlation with clinical outcome in patients with chronic-phase chronic myeloid leukemia for 400mg and 800mg daily doses (Tyrosine Kinase Dose Optimization Study [TOPS])","volume":"112","author":"Guilhot","year":"2008","journal-title":"Blood"},{"key":"10.1016\/j.beha.2009.04.005_bib80","doi-asserted-by":"crossref","first-page":"4445","DOI":"10.1200\/JCO.2006.09.9499","article-title":"Measurement of in vivo BCR-ABL kinase inhibition to monitor imatinib-induced target blockage and predict response in chronic myeloid leukemia","volume":"25","author":"White","year":"2007","journal-title":"J Clin Oncol"},{"key":"10.1016\/j.beha.2009.04.005_bib81","doi-asserted-by":"crossref","first-page":"1200","DOI":"10.1038\/leu.2008.84","article-title":"Dasatinib induces durable cytogenetic responses in patients with chronic myelogenous leukemia in chronic phase with resistance or intolerance to imatinib","volume":"22","author":"Hochhaus","year":"2008","journal-title":"Leukemia"},{"key":"10.1016\/j.beha.2009.04.005_bib82","doi-asserted-by":"crossref","first-page":"3540","DOI":"10.1182\/blood-2007-03-080689","article-title":"Nilotinib (formerly AMN107), a highly selective BCR-ABL tyrosine kinase inhibitor, is effective in patients with Philadelphia chromosome-positive chronic myelogenous leukemia in chronic phase following imatinib resistance and intolerance","volume":"110","author":"Kantarjian","year":"2007","journal-title":"Blood"},{"key":"10.1016\/j.beha.2009.04.005_bib83","doi-asserted-by":"crossref","first-page":"516","DOI":"10.1182\/blood-2008-02-141580","article-title":"Failure to achieve a major cytogenetic response by 12 months defines inadequate response in patients receiving nilotinib or dasatinib as second or subsequent line therapy for chronic myeloid leukemia","volume":"112","author":"Tam","year":"2008","journal-title":"Blood"},{"key":"10.1016\/j.beha.2009.04.005_bib84","doi-asserted-by":"crossref","DOI":"10.1182\/blood.V112.11.332.332","article-title":"Prediction of cytogenetic response to second generation TKI therapy in CML chronic phase patients who have failed imatinib therapy and early identification of factors that influence survival","volume":"112","author":"Milojkovic","year":"2008","journal-title":"Blood"}],"container-title":["Best Practice & Research Clinical Haematology"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S1521692609000218?httpAccept=text\/xml","content-type":"text\/xml","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S1521692609000218?httpAccept=text\/plain","content-type":"text\/plain","content-version":"vor","intended-application":"text-mining"}],"deposited":{"date-parts":[[2020,5,24]],"date-time":"2020-05-24T00:59:14Z","timestamp":1590281954000},"score":1,"resource":{"primary":{"URL":"https:\/\/linkinghub.elsevier.com\/retrieve\/pii\/S1521692609000218"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2009,9]]},"references-count":84,"journal-issue":{"issue":"3","published-print":{"date-parts":[[2009,9]]}},"alternative-id":["S1521692609000218"],"URL":"https:\/\/doi.org\/10.1016\/j.beha.2009.04.005","relation":{},"ISSN":["1521-6926"],"issn-type":[{"value":"1521-6926","type":"print"}],"subject":[],"published":{"date-parts":[[2009,9]]}}}